The Art and Science of Building a Computational Model to Understand Hemostasis
- PMID: 33657623
- PMCID: PMC7920145
- DOI: 10.1055/s-0041-1722861
The Art and Science of Building a Computational Model to Understand Hemostasis
Abstract
Computational models of various facets of hemostasis and thrombosis have increased substantially in the last decade. These models have the potential to make predictions that can uncover new mechanisms within the complex dynamics of thrombus formation. However, these predictions are only as good as the data and assumptions they are built upon, and therefore model building requires intimate coupling with experiments. The objective of this article is to guide the reader through how a computational model is built and how it can inform and be refined by experiments. This is accomplished by answering six questions facing the model builder: (1) Why make a model? (2) What kind of model should be built? (3) How is the model built? (4) Is the model a "good" model? (5) Do we believe the model? (6) Is the model useful? These questions are answered in the context of a model of thrombus formation that has been successfully applied to understanding the interplay between blood flow, platelet deposition, and coagulation and in identifying potential modifiers of thrombin generation in hemophilia A.
The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Conflict of interest statement
K.B.N. reports grants from National Institutes of Health, during the conduct of the study. D.M.M. reports grants from Army Research Office, during the conduct of the study.
Figures



References
-
- Wang S, Guo P, Wang X, Zhou Q, Gallo J M. Preclinical pharmacokinetic/pharmacodynamic models of gefitinib and the design of equivalent dosing regimens in EGFR wild-type and mutant tumor models. Mol Cancer Ther. 2008;7(02):407–417. - PubMed
-
- Jurgens J. The exponentiator; a nomogram for uniform quick percentile determination of the blood coagulation factors [in German] Arztl Wochensch. 1954;9(18):420–422. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources